Rethinking Early Intervention in Relapsing MS
Expert insights on the open-label DAYBREAK study of ozanimod for early relapsing MS: efficacy, long-term safety, and real-world use from…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
